RE:Trials.... Will they go like Empower.Sorry, the nonsense you have been spewing deserves a response. On December the 9th you commented that MedX finally knows how to communicate to shareholders and that you hoped everyone was paying attention. A month later you are back stating MedX never communicates. Well there was a holiday season in there so putting out any news on December 25th would likely haven fallen on deaf ears.
But lets look at your other statements and challenge their validity. Firstly, large companies are under NDA's and would never tell some little investor any material information about the state of a potential contract. However, making a declarative, material statement that is patently false could land you in a lot of trouble with the OSC.Especially when you try and share that false information through your PM. So I would encourage you to careful, you don't deserve that kind of trouble. You do deserve to understand what your investment is doing.
The Empower Clinics and walk-ins. I don't think you really understand the model. You calling a clinic when they first open and asking a clinic manager questions to gains some stock market insight would be like going to a McDonalds drive through line and asking the order taker how many fries they are going to sell today. Interesting but a small useless dataset. So here is the better answer, the Empower clinic on Brown's Line stated they have a 10,000 patient roster. I think that is their target market not you wondering in off the street. MedX has stated that they do not expect revenue in their forecasts until 1 month after the clinic is up and running.
The pilots in Europe are designed to run for 3-6 months and during that time they pay for the hardware and the scans. Once a pilot is finished they convert into a contract. This has been explained on numerous podcasts. I need a break from this site because it was becoming difficult to read the nonsense.
Your other statement regarding institutional investors....what are you talking about? Maybe a few microcap managers might own shares in a company with this small a market cap or a few family trusts but MedX is way too small for any real institution funds to own shares. They have strict liquidity and capitalization benchmarks before they are allowed to invest as set out in their investment policy statement.
Look at the end of the day MedX has taken much longer to get to the market partially because the medical device business has a slow adoption curve and partially because we have been in a global pandemic. However if you go to the news releases in December and actually read them you will see MedX has made a lot of progress in the past quarter. I expect more news supporting their strategy over the ensuing months.
Remember the big hype because one med-student caught a potential melanoma at a hockey game, MedX does this every day.They have stated they have detected over 1,500 melanomas so that is a lot of season's tickets.
Look at the videos on this site and tell me MedX doesn't make a difference;
https://www.linkedin.com/company/medx-health-corp/posts/?feedView=all
Hope this gives a more balanced perspective.
MedX in the news;
https://medxhealth.com/in-the-media